Show simple item record

dc.contributor.authorReiter, Andreas
dc.contributor.authorWalz, Christoph
dc.contributor.authorWatmore, Ann
dc.contributor.authorSchoch, Claudia
dc.contributor.authorBlau, Ilona
dc.contributor.authorSchlegelberger, Brigitte
dc.contributor.authorBerger, Ute
dc.contributor.authorTelford, Nicholas
dc.contributor.authorAruliah, Shilani
dc.contributor.authorYin, John A
dc.contributor.authorVanstraelen, Danny
dc.contributor.authorBarker, Helen F
dc.contributor.authorTaylor, Peter C
dc.contributor.authorO'Driscoll, Aisling
dc.contributor.authorBenedetti, Fabio
dc.contributor.authorRudolph, Cornelia
dc.contributor.authorKolb, Hans-Jochem
dc.contributor.authorHochhaus, Andreas
dc.contributor.authorHehlmann, Rüdiger
dc.contributor.authorChase, Andrew
dc.contributor.authorCross, Nicholas C P
dc.date.accessioned2009-07-22T10:07:54Z
dc.date.available2009-07-22T10:07:54Z
dc.date.issued2005-04-01
dc.identifier.citationThe t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. 2005, 65 (7):2662-7 Cancer Res.en
dc.identifier.issn0008-5472
dc.identifier.pmid15805263
dc.identifier.doi10.1158/0008-5472.CAN-04-4263
dc.identifier.urihttp://hdl.handle.net/10541/74917
dc.description.abstractWe have identified a t(8;9)(p21-23;p23-24) in seven male patients (mean age 50, range 32-74) with diverse hematologic malignancies and clinical outcomes: atypical chronic myeloid leukemia/chronic eosinophilic leukemia (n = 5), secondary acute myeloid leukemia (n = 1), and pre-B-cell acute lymphoblastic leukemia (n = 1). Initial fluorescence in situ hybridization studies of one patient indicated that the nonreceptor tyrosine kinase Janus-activated kinase 2 (JAK2) at 9p24 was disrupted. Rapid amplification of cDNA ends-PCR identified the 8p22 partner gene as human autoantigen pericentriolar material (PCM1), a gene encoding a large centrosomal protein with multiple coiled-coil domains. Reverse transcription-PCR and fluorescence in situ hybridization confirmed the fusion in this case and also identified PCM1-JAK2 in the six other t(8;9) patients. The breakpoints were variable in both genes, but in all cases the chimeric mRNA is predicted to encode a protein that retains several of the predicted coiled-coil domains from PCM1 and the entire tyrosine kinase domain of JAK2. Reciprocal JAK2-PCM1 mRNA was not detected in any patient. We conclude that human autoantigen pericentriolar material (PCM1)-JAK2 is a novel, recurrent fusion gene in hematologic malignancies. Patients with PCM1-JAK2 disease are attractive candidates for targeted signal transduction therapy.
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subject.meshAcute Disease
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAmino Acid Sequence
dc.subject.meshAutoantigens
dc.subject.meshBase Sequence
dc.subject.meshCell Cycle Proteins
dc.subject.meshChromosomes, Human, Pair 8
dc.subject.meshChromosomes, Human, Pair 9
dc.subject.meshHumans
dc.subject.meshJanus Kinase 2
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subject.meshLeukemia, Myeloid
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMolecular Sequence Data
dc.subject.meshOncogene Proteins, Fusion
dc.subject.meshProtein-Tyrosine Kinases
dc.subject.meshProto-Oncogene Proteins
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
dc.subject.meshTranslocation, Genetic
dc.titleThe t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.en
dc.typeArticleen
dc.contributor.departmentIII. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany. andreas.reiter@med3.ma.uni-heidelberg.deen
dc.identifier.journalCancer Researchen
html.description.abstractWe have identified a t(8;9)(p21-23;p23-24) in seven male patients (mean age 50, range 32-74) with diverse hematologic malignancies and clinical outcomes: atypical chronic myeloid leukemia/chronic eosinophilic leukemia (n = 5), secondary acute myeloid leukemia (n = 1), and pre-B-cell acute lymphoblastic leukemia (n = 1). Initial fluorescence in situ hybridization studies of one patient indicated that the nonreceptor tyrosine kinase Janus-activated kinase 2 (JAK2) at 9p24 was disrupted. Rapid amplification of cDNA ends-PCR identified the 8p22 partner gene as human autoantigen pericentriolar material (PCM1), a gene encoding a large centrosomal protein with multiple coiled-coil domains. Reverse transcription-PCR and fluorescence in situ hybridization confirmed the fusion in this case and also identified PCM1-JAK2 in the six other t(8;9) patients. The breakpoints were variable in both genes, but in all cases the chimeric mRNA is predicted to encode a protein that retains several of the predicted coiled-coil domains from PCM1 and the entire tyrosine kinase domain of JAK2. Reciprocal JAK2-PCM1 mRNA was not detected in any patient. We conclude that human autoantigen pericentriolar material (PCM1)-JAK2 is a novel, recurrent fusion gene in hematologic malignancies. Patients with PCM1-JAK2 disease are attractive candidates for targeted signal transduction therapy.


This item appears in the following Collection(s)

Show simple item record